JNJ Stock Rebounds as ICOTYDE Shows Strong Psoriasis Results Through Two Years

Johnson & Johnson's (JNJ) stock price has rebounded by 0.54% in pre-market trading after falling 2.30% in the previous session, reaching $260.21.

The increase follows the release of new two-year Phase 3 data for ICOTYDE in patients with plaque psoriasis, showing sustained skin clearance across several high-impact body areas through Week 112.

According to the study, 70% of patients achieved clear or almost clear skin by Week 112, while complete clearance was reached for genital psoriasis (89%) and scalp cases (60%).